高盛研究报告指，上海医药(02607.HK) 首季收入按年增长6.4%至753亿元人民币(下同)，基本符合该行及市场预期。盈利按年增长6.4%至14亿元，符合该行预期；毛利率由去年同期的10%轻微扩张至10.4%。该行将2026至2028年净利润预测分别上调5%、3%及3.6%，维持“沽售”评级，目标价由10.3港元升至10.63港元。该行认为，在仿制药及医械带量采购(VBP)常态化下，公司利润率...
Source Link高盛研究报告指，上海医药(02607.HK) 首季收入按年增长6.4%至753亿元人民币(下同)，基本符合该行及市场预期。盈利按年增长6.4%至14亿元，符合该行预期；毛利率由去年同期的10%轻微扩张至10.4%。该行将2026至2028年净利润预测分别上调5%、3%及3.6%，维持“沽售”评级，目标价由10.3港元升至10.63港元。该行认为，在仿制药及医械带量采购(VBP)常态化下，公司利润率...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.